Stimuli-responsive prodrug-based cancer nanomedicine
| Autor: | Zhongmin Tang, Baowen Qi, Angel Xie, Na Kong, Wei Tao, Bingyang Shi, Jiang Ouyang, Dylan Neal Patel, Sumaira Hanif, Na Yoon Kim |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Stimuli responsive Cancer therapy lcsh:Medicine Nanotechnology Review General Biochemistry Genetics and Molecular Biology 03 medical and health sciences 0302 clinical medicine Neoplasms Humans Medicine Prodrugs Prodrug Polymer lcsh:R5-920 business.industry lcsh:R General Medicine Patient data Stimuli-responsive Hydrogen-Ion Concentration Oxidative Stress 030104 developmental biology Nanomedicine 030220 oncology & carcinogenesis Nanoparticles business lcsh:Medicine (General) |
| Zdroj: | EBioMedicine, Vol 56, Iss, Pp 102821-(2020) EBioMedicine |
| ISSN: | 2352-3964 |
| Popis: | The rapid development of nanotechnology results in the emergence of nanomedicines, but the effective delivery of drugs to tumor sites remains a great challenge. Prodrug-based cancer nanomedicines thus emerged due to their unique advantages, including high drug load efficiency, reduced side effects, efficient targeting, and real-time controllability. A distinctive characteristic of prodrug-based nanomedicines is that they need to be activated by a stimulus or multi-stimulus to produce an anti-tumor effect. A better understanding of various responsive approaches could allow researchers to perceive the mechanism of prodrug-based nanomedicines effectively and further optimize their design strategy. In this review, we highlight the stimuli-responsive pathway of prodrug-based nanomedicines and their anticancer applications. Furthermore, various types of prodrug-based nanomedicines, recent progress and prospects of stimuli-responsive prodrug-based nanomedicines and patient data in the clinical application are also summarized. Additionally, the current development and future challenges of prodrug-based nanomedicines are discussed. We expect that this review will be valuable for readers to gain a deeper understanding of the structure and development of prodrug-based cancer nanomedicines to design rational and effective drugs for clinical use. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|